Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02091960 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
A Phase 2 study of Advanced Breast Cancer and HER2 Amplified, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
- 20
- Study locations
NCT02091960 is a Phase 2 study of Advanced Breast Cancer and HER2 Amplified that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 103 participants, below the 461-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT02091960, a Phase 2 study of Advanced Breast Cancer and HER2 Amplified, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to evaluate the efficacy of enzalutamide with trastuzumab in patients with HER2+ AR+ metastatic or locally advanced breast cancer.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Enzalutamide
Study Locations (20)
California
- Site US10051 - Anaheim
- Site US10028 - Los Angeles
- Site US10035 - San Francisco
Tennessee
- Site US10029 - Knoxville
- Site US10042 - Nashville
- Site US10077 - Nashville
Other
- Site BE32013 - Brasschaat
- Site BE32016 - Brussels
- Site BE32001 - Charleroi
Florida
- Site US10079 - Fort Myers
- Site US10074 - Gainesville
Texas
- Site US10076 - Fort Worth
- Site US10082 - Houston
Illinois
- Site US10081 - Chicago
Indiana
- Site US10004 - Indianapolis
Massachusetts
- Site US10070 - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2014-09-05 |
| Est. Completion | 2024-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02091960
The ClinicalTrials.gov registry entry for NCT02091960 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 461-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Advanced Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Trastuzumab is the first listed.
NCT02091960 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Tennessee, Other.
Frequently Asked Questions
What is clinical trial NCT02091960 about?
NCT02091960 is a clinical study titled "A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer". The purpose of this study was to evaluate the efficacy of enzalutamide with trastuzumab in patients with HER2+ AR+ metastatic or locally advanced breast cancer.
What is the current status of trial NCT02091960?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2014-09-05. Estimated completion is 2024-01-30.
What conditions does trial NCT02091960 study?
This clinical trial studies the following conditions: Advanced Breast Cancer, HER2 Amplified, Human Epidermal Growth Factor Receptor 2 (HER2).
What interventions are being tested in trial NCT02091960?
The interventions under investigation include: Trastuzumab (DRUG), Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT02091960?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02091960 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
RECRUITING · Phase 2
-
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
RECRUITING · Phase 2
-
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
ACTIVE NOT RECRUITING · Phase 2
-
RCT of CBD for Anxiety in Advanced Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.